Evanston, IL, United States of America

Michael G Fickes

USPTO Granted Patents = 5 

 

 

Average Co-Inventor Count = 5.4

ph-index = 1


Location History:

  • Evanston, IL (US) (2013 - 2016)
  • Lake Bluff, IL (US) (2017 - 2022)

Company Filing History:


Years Active: 2013-2022

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):

Title: Michael G Fickes: Innovator in Crystalline Forms

Introduction: Michael G Fickes is an accomplished inventor based in Evanston, IL, known for his impactful contributions in the field of pharmaceuticals. With a total of five patents to his name, Fickes has demonstrated a commitment to advancing drug formulations through innovative crystalline structures.

Latest Patents: Among his recent innovations, Fickes has focused on the crystallization of Compound I. His latest patents detail the crystalline forms of this compound, showcasing specific characteristics in the PXRD pattern. These advancements not only enhance the understanding of the compound's properties but also pave the way for improved pharmaceutical applications.

Career Highlights: Michael G Fickes has gained valuable experience by working with renowned companies such as AbbVie Inc. and Abbott Laboratories Corporation. His tenure in these healthcare giants has allowed him to deepen his expertise and contribute to significant advancements in drug development.

Collaborations: Throughout his career, Fickes has collaborated with notable colleagues, including Jean-Christophe C Califano and Lars Fredrik Nordström. These professional relationships have enabled the exchange of ideas and fostered a collaborative environment, ultimately leading to groundbreaking developments in their respective fields.

Conclusion: Michael G Fickes stands out as a notable inventor whose work in crystalline forms has the potential to revolutionize pharmaceutical formulations. His dedication to innovation, combined with a strong foundation in industry collaborations, positions him as a significant contributor to the advancement of drug development technologies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…